Gene · 962
NIH grants2,184
NIH grants whose papers are about the gene, through NIH's grant-paper links.
201 to 220 of 2,184
Download this page as JSON| Grant | Title | CD48 papers | Newest fiscal year |
|---|---|---|---|
| R01AI124355 | Genetic and Immunological Dissection of Eosinophilic Esophagitis | 1 | 2025 |
| R01AI125640 | Novel mechanisms regulating PD-1 signaling and function | 1 | 2025 |
| R01AI145486 | V-OLA point-of-care HIV viral load monitoring and drug resistance testing | 1 | 2025 |
| R01AI152183 | Immune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study) | 1 | 2025 |
| R01AI159260 | MHC Variation in Host Response to SARS-CoV2 and COVID-19 Outcomes | 1 | 2025 |
| R01AI172089 | Critical role for Solute Carrier Proteins (SLCs) for mast cell function | 1 | 2025 |
| R01AR078268 | Investigating Mucosal Breaks in the Initiation and Progression of Rheumatoid Arthritis | 1 | 2025 |
| R01CA047296 | A Pathway of Tumor Suppression | 1 | 2025 |
| R01CA097098 | Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer | 1 | 2025 |
| R01CA104509 | Molecular Mechanism of Leukemogenesis involving AML1-ETO | 1 | 2025 |
| R01CA142779 | PD-1/PD-L1 modulation in cancer therapy | 1 | 2025 |
| R01CA152108 | Molecular and Cellular Mechanisms of Chronic Myelomonocytic Leukemia (CMML) | 1 | 2025 |
| R01CA154426 | Colorectal carcinogenesis and Fusobacterium nucleatum: oncomicrobe, oncometabolites, and oncoimmunology | 1 | 2025 |
| R01CA163217 | Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma | 1 | 2025 |
| R01CA166835 | Targeted therapy for t(8;21)+ AML | 1 | 2025 |
| R01CA183252 | DNMT3A in Development of Hematologic Malignancies | 1 | 2025 |
| R01CA203348 | Expression of recombinant Fc receptors by engineered NK cells to enhance cancer cell killing | 1 | 2025 |
| R01CA215226 | Therapeutic Targeting of RNA Splicing in Triple-Negative Breast Cancer | 1 | 2025 |
| R01CA217987 | Metabolic barriers to T cell activation in clear cell renal cell carcinoma | 1 | 2025 |
| R01CA248794 | Leukemia stem cell regulation and resistance | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/962/grants?page=11